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Abstract
Objective: Niacin potently lowers triglycerides, mildly decreases LDL-cholesterol, and largely increases HDL-cholesterol.
Despite evidence for an atheroprotective effect of niacin from previous small clinical studies, the large outcome trials, AIM-
HIGH and HPS2-THRIVE did not reveal additional beneficial effects of niacin (alone or in combination with laropiprant) on
top of statin treatment. We aimed to address this apparent discrepancy by investigating the effects of niacin without and
with simvastatin on atherosclerosis development and determine the underlying mechanisms, in APOE*3Leiden.CETP mice, a
model for familial dysbetalipoproteinemia (FD).
Approach and Results: Mice were fed a western-type diet containing cholesterol without or with niacin (120 mg/kg/day),
simvastatin (36 mg/kg/day) or their combination for 18 weeks. Similarly as in FD patients, niacin reduced total cholesterol
by -39% and triglycerides by 250%, (both P,0.001). Simvastatin and the combination reduced total cholesterol (230%;
255%, P,0.001) where the combination revealed a greater reduction compared to simvastatin (236%, P,0.001). Niacin
decreased total cholesterol and triglycerides primarily by increasing VLDL clearance. Niacin increased HDL-cholesterol
(+28%, P,0.01) and mildly increased reverse cholesterol transport. All treatments reduced monocyte adhesion to the
endothelium (246%; 247%, P,0.01; 253%, P,0.001), atherosclerotic lesion area (278%; 249%, P,0.01; 287%, P,0.001)
and severity. Compared to simvastatin, the combination increased plaque stability index [(SMC+collagen)/macrophages] (3-
fold, P,0.01). Niacin and the combination reduced T cells in the aortic root (271%, P,0.01; 281%, P,0.001). Lesion area
was strongly predicted by nonHDL-cholesterol (R2 = 0.69, P,0.001) and to a much lesser extent by HDL-cholesterol
(R2 = 0.20, P,0.001).
Conclusion: Niacin decreases atherosclerosis development mainly by reducing nonHDL-cholesterol with modest HDL-
cholesterol-raising and additional anti-inflammatory effects. The additive effect of niacin on top of simvastatin is mostly
dependent on its nonHDL-cholesterol-lowering capacities. These data suggest that clinical beneficial effects of niacin are
largely dependent on its ability to lower LDL-cholesterol on top of concomitant lipid-lowering therapy.
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Introduction
The beneficial effects of niacin, also known as nicotinic acid or
vitamin B3, on plasma lipids and lipoproteins were first described
in the 1950s [1]. According to a meta-analysis of 30 randomized
controlled trials, niacin potently reduced triglycerides (TG) by
,15–30% and increased HDL-cholesterol (HDL-C) by ,10–
25%, while mildly reducing plasma total cholesterol (TC) by ,5–
15% and LDL-cholesterol (LDL-C) by ,5–20%, suggesting an
atheroprotective effect [2]. Whereas previous small clinical studies
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supported this notion [3–6], the recent large outcome trials AIM-
HIGH and HPS2-THRIVE failed to reveal additional beneficial
effects of niacin on top of statin treatment [7,8].
In patients with atherosclerotic disease or those at risk for
atherosclerotic disease due to dyslipidemia, the primary goal of
lipid-modifying therapy is the lowering of LDL-C [9]. To this end,
statins are currently the standard treatment for cardiovascular
disease (CVD) resulting in a 25–45% risk reduction for cardio-
vascular events [10]. However, a substantial residual risk for
adverse cardiovascular outcomes remains with statin therapy
[3,11]. Moreover, despite maximally tolerated statin treatment,
some patients cannot reach LDL-C goals. This high risk
population together with statin intolerant patients verify the need
for another LDL-C-lowering agent to (further) reduce LDL-C
levels [12]. Treatment of low HDL-C is currently considered a
secondary lipid target in the reduction of cardiovascular risk [3],
since low HDL-C is an independent risk factor for CVD [2,13].
Considering the current treatment options, the question remains
whether to further reduce LDL-C or to increase HDL-C in
addition to LDL-C-lowering [12]. Therefore, due to both its
nonHDL-C-lowering and HDL-C-raising properties, niacin was
considered an attractive candidate for further cardiovascular risk
reduction in addition to statin therapy.
Indeed, an initial small clinical study suggested that the addition
of niacin to statin treatment may cause potentially clinical
significant reductions in relative risk of cardiovascular events [6].
Recently a number of relatively small secondary prevention studies
(ARBITER-2 [4], ARBITER-3 [5] and ARBITER-6-HALTS [3])
have shown reduced progression and even regression of athero-
sclerosis with combination treatment of niacin and statins
compared to statins alone, as measured by carotid artery intima
media thickness as a surrogate for clinical endpoints. Magnetic
resonance imaging results from another study confirmed the
reduction in carotid atherosclerosis with niacin in statin-treated
patients [14]. These clinical data were corroborated by recent
observations that niacin reduces atherosclerosis development,
independent of lipid-lowering or HDL-C-elevation, in hyperlipid-
emic LDL receptor knockout mice on a high fat diet containing
1.5% cholesterol [15]. Despite these promising data, the large
outcome trial, AIM-HIGH, addressing the effect of niacin on top
of aggressive LDL-lowering treatment, has recently been prema-
turely terminated due to futility [8]. In accordance, the much
larger HPS2-THRIVE trial failed to reveal additional risk
reduction of cardiovascular events with extended-release (ER)-
niacin/laropiprant in combination with statin treatment as
compared to statin mono-treatment [7]. ER-niacin [2] and ER-
niacin/laropiprant combination treatment [16] are more tolerable
formulations that have been developed due to a reluctance to use
niacin for clinical treatment as a result of extreme flushing as a side
effect [17].
In the present study, we aimed to address the seeming
discrepancy between the beneficial effects of niacin in initial
clinical trials, [3–6,14] as well as in LDL receptor knockout mice, a
model irresponsive to the lipid-modulating effects of niacin [15],
and the lack of effect of niacin on top of statin treatment on
reduction of cardiovascular events in the AIM-HIGH [8] and
HPS2-THRIVE trials [7]. Therefore, we evaluated the effects of
niacin without and with simvastatin on atherosclerosis develop-
ment and investigated the underlying mechanisms and contribut-
ing factors in APOE*3Leiden.CETP mice. This is a well-
established mouse model for familial dysbetalipoproteinemia
(FD) with human-like lipoprotein metabolism and atherosclerosis
development. These mice respond to the lipid-lowering effects of
both niacin [18] and statins, e.g. atorvastatin [19], as well as the
HDL-C-raising effect of niacin [18].
Methods
Animals, Diets and Experimental Design
Female APOE*3Leiden.CETP transgenic mice [20], expressing
human cholesteryl ester transfer protein (CETP) under control of
its natural flanking regions, were housed under standard
conditions with a 12 h light-dark cycle and had free access to
food and water during the experiment unless indicated otherwise.
Body weight (BW) and food intake were monitored during the
entire study. To increase plasma cholesterol levels up to
,12 mmol/L, 8–12 week-old mice were fed a semi-synthetic
cholesterol-rich diet, containing 15% (w/w) cacao butter and 0.1%
cholesterol (Western-type diet; Hope Farms, Woerden, The
Netherlands) for 3 weeks. After matching based on age, BW,
TC, TG and HDL-C mice (n = 15 per group) received a control
western-type diet (WTD) without or with 0.1% (w/w) niacin
(120 mg/kg/day), 0.03% (w/w) simvastatin (36 mg/kg/day) or
their combination for 18 weeks. During the treatment period, the
effects of treatment on plasma lipids, lipoprotein profiles, CETP
activity and CETP mass were assessed at the indicated time points.
The dose of simvastatin targeted a 30–35% reduction in TC
and that of niacin a 20–30% increase in HDL-C. While we
achieved these targets, it should be noted that the dose of
simvastatin was 3 times higher than the maximum dose used in the
clinic taking into account a 10 times faster metabolism in mice. For
niacin the dose was comparable to that in patients, about 1 g/day.
At the end of the experiment all animals were sacrificed by CO2
inhalation. Liver and white adipose tissue (WAT) were isolated to
assess CETP expression (n= 6–8 per group) and hearts were
isolated to assess atherosclerosis development (n = 15 per group).
Separate additional experiments were performed to evaluate the
effects of niacin on VLDL production and clearance, as well as
reverse cholesterol transport (RCT). Animal experiments were
approved by the Institutional Animal Care and Use Committee of
The Netherlands Organization for Applied Research (TNO).
Plasma Lipids and Lipoprotein Profiles
After a 4 h fast, blood was collected via tail vein bleeding and
plasma was isolated. Plasma TC, HDL-C after precipitation of
apoB-containing lipoproteins using MnCl2 [21] and TG were
determined individually using enzymatic kits 1489437 and
1488872 (both from Roche diagnostics), according to the
manufacturer’s protocols. After 4 and 18 weeks of treatment,
pooled lipoprotein profiles for TC were measured by fast protein
liquid chromatography (FPLC) [20].
VLDL Production and Clearance Experiments
APOE*3Leiden.CETP mice (11–14 weeks of age) were fed a
WTD containing 0.1% cholesterol for 3 weeks. Upon subsequent
matching according to plasma TC and TG levels, mice received
the cholesterol-containing WTD without or with 0.1% (w/w)
niacin for an additional 3 weeks [18] and VLDL production and
clearance were determined as described [22].
Plasma was obtained via tail vein bleeding in heparin
microvettes for randomization (Sarstedt, Germany) and in chilled
paraoxon-coated capillary tubes to prevent ex vivo TG hydrolysis
for VLDL production and clearance, and assayed for TG and TC
using commercially available kits 1488872 and 236691 (Roche
Molecular Biochemicals, Indianapolis, IN, USA), respectively.
For the VLDL production experiment, 6 control and 6 niacin-
treated mice were fasted for 4 h. During the experiment, mice
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were sedated with 6.25 mg/kg acepromazine (Alfasan), 6.25 mg/
kg midazolam (Roche) and 0.31 mg/kg fentanyl (Janssen-Cilag).
At t = 0 min, blood was taken via tail bleeding and mice were
injected intravenously with 100 mL PBS containing 100 mCi
Trans35S label to measure de novo total apoB synthesis. After
30 min, the mice received 500 mg of tyloxapol (Triton WR-1339,
Sigma-Aldrich) per kg BW as a 10% (w/w) solution in sterile
saline, to prevent systemic lipolysis of newly secreted hepatic
VLDL-TG. Additional blood samples were taken 15, 30, 60, and
90 min after tyloxapol injection and used for determination of
plasma TG concentration. After 120 min, the mice were sacrificed
and blood was collected by orbital puncture for isolation of VLDL
by density gradient ultracentrifugation. Incorporation of 35S-label
was measured in the VLDL fraction as marker of de novo apoB
synthesis.
For the VLDL clearance experiment, glycerol tri[3H]oleate
(triolein, TO)- and [1a,2a(n)-14C]cholesteryl oleate (CO)-double
labeled VLDL-like emulsion particles (80 nm) were used [23]. In
short, radiolabeled emulsions were obtained by adding 100 mCi of
[3H]TO and 10 mCi of [14C]CO to 100 mg of emulsion lipids
before sonication (isotopes obtained from GE Healthcare, Little
Chalfont, U.K.). APOE*3Leiden.CETP mice (5 control and 5
niacin-treated mice) were fasted for 4 h, sedated as described
above, and injected intravenously with the radiolabeled emulsion
particles (1.0 mg TG in 200 mL PBS). Blood was taken from the
tail vein to determine the content of [3H]TO and [14C]CO in
serum at 2, 5, 10 and 15 min after emulsion injection. Fifteen min
after injection, plasma was collected by orbital puncture and mice
were sacrificed by cervical dislocation. Organs were harvested and
saponified to determine uptake of radioactivity derived from
[3H]TO and [14C]CO by various organs [22].
Endogenous CETP Activity, CETP Mass and CETP mRNA
Expression Analysis
Plasma endogenous CETP activity was determined by a
fluorescent method using donor liposomes enriched with nitro-
benzoxadiazole-labeled cholesteryl esters (RB-CETP, Roar Bio-
medical, New York, NY) as described [19]. CETP activity was
calculated as nmol cholesteryl ester transfer/mL plasma/h.
Plasma CETP mass was determined by using the DAIICHI
CETP ELISA kit according to manufacturer’s instructions
(Daiichi, Tokyo, Japan) [18]. Total RNA was extracted from liver
and white adipose tissue (WAT) using an RNA isolation kit
according to manufacturer’s specifications (Macherey-Nagel,
Du¨ren, Germany). Total RNA concentrations were measured
with Nanodrop. One mg of RNA was reversed-transcribed to
cDNA with iScriptcDNA Synthesis kit (Bio-Rad) and purified with
Nucleospin Extract II kit (Macherey-Nagel, Du¨ren, Germany).
Real-time PCR (RT-PCR) was carried out on an iQ5 PCR
detection system (Bio-Rad) using Sensimix SYBR Green RT-PCR
mix (Quantace, London, UK). Hypoxanthine-guanine phospor-
ibosyltransferase (HPRT) and acidic ribosomal phosphoprotein
PO (36B4) were used as the standard housekeeping genes and
expression levels were normalized to these housekeeping genes.
Primer sequences are listed in Table S1.
Histological Assessment of Atherosclerosis
After isolation, hearts were fixed in formalin, embedded in
paraffin and cross-sectioned (5 mm) throughout the aortic root
area. For each mouse, four sections at intervals of 50 mm were
used for quantitative and qualitative assessment of the atheroscle-
rotic lesions after staining with hematoxylin-phloxin-saffron. For
determination of severity of atherosclerosis, the lesions were
classified into five categories: I) early fatty streak, II) regular fatty
streak, III) mild plaque, IV) moderate plaque, and V) severe
plaque according to the American Heart Association classification
[19,24]. Lesion severity as a percentage of the number of lesions
was calculated. To this end, type I–III lesions were classified as
mild lesions and type IV–V lesions were classified as severe lesions.
Total lesion area and number of lesions per cross section, as well as
the percentage undiseased segments, were calculated. In each
segment used for lesion quantification, the number of monocytes
adhering to the endothelium and the numbers of T cells in the
total aortic root area were counted after immunostaining with AIA
31240 antibody (1:1000; Accurate Chemical and Scientific, New
York, New York, USA) and CD3 (1:500; AbD Serotec, Oxford,
UK), respectively. Macrophage content of the lesions was
measured after immunostaining with Mac-3 (1:50; BD Pharmin-
gen, the Netherlands). In addition, sirius red staining was used to
quantify the collagen content in the plaque [25] and the antibody
alpha actin (1:800; DAKO, Glostrup, Denmark) was used to
quantify the smooth muscle cell (SMC) content [26]. Stained areas
were measured using Cell D imaging software (Olympus Soft
Imaging Solutions).
Reverse Cholesterol Transport Experiment
16 recipient APOE*3Leiden.CETP mice (10–12 weeks of age)
were fed a WTD containing 0.1% cholesterol for a run-in period
of 3 weeks after which they were subdivided into 2 groups
according to age, BW, TC, TG and HDL-C. After matching, mice
(n = 8 per group) received a control cholesterol-containing WTD
without or with 0.1% (w/w) niacin (120 mg/kg/day) for 3 weeks.
6 donor APOE*3Leiden.CETP mice (10–12 weeks of age) fed a
WTD containing 0.1% cholesterol for 3 weeks were injected
intraperitoneally with 1 mL solution of 3% thioglycollate to induce
an inflammatory response. Three days after the injection, mice
were injected intraperitoneally with approximately 300 mCi [3H]-
cholesterol together with 100 mg/mL acetylated LDL. Mice were
sacrificed 1 h later by CO2 inhalation. [
3H]-cholesterol-labeled
macrophages were collected from the 6 donor mice by peritoneal
lavage. These macrophages were washed twice with cold PBS and
injected intraperitoneally into the 16 recipient APOE*3Leiden.-
CETP mice. Each recipient mouse received 2.86106 [3H]-
cholesterol-labeled macrophages containing 7.86106 dpm [3H]-
cholesterol. Mice were individually caged for 48 h in order to
collect feces and sacrificed by CO2 inhalation.
3H-activity was
determined in the plasma, liver and feces. The in vivo RCT
experiment was based on methods previously described [27,28].
Statistical Analyses
Significance of differences between the groups was calculated
non-parametrically using a Kruskal-Wallis test followed by a
Mann-Whitney U-test for independent samples. We performed a
univariate analysis of variance (ANOVA) to investigate the role of
TC, nonHDL-C and HDL-C exposure as contributing factors in
lesion development. A two-way analysis of covariance (ANCOVA)
was performed to test for group differences in lesion area,
monocyte adhesion, T cell abundance and macrophage area after
correcting for HDL-C and nonHDL-C exposure. SPSS 17.0 for
Windows (SPSS, Chicago, USA) was used for statistical analysis.
All groups were compared to the control group and the
combination group was also compared to the simvastatin group.
Values are presented as means 6 SD. P-values ,0.05 were
considered statistically significant. In the figures, the symbol * is
used to compare to the control group, and # to compare to the
simvastatin group.
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Results
Niacin, Simvastatin and their Combination Reduce
Plasma Total Cholesterol and Triglycerides and Niacin
Increases HDL-C in APOE*3Leiden.CETP Mice
To verify the lipid-lowering effect of niacin alone and in
combination with simvastatin, we measured plasma TC
(Figure 1A), TG (Figure 1B) and HDL-C (Figure 1C) levels
during the study. The western-type diet resulted in an average TC
of 13.461.7 mmol/L, TG of 4.361.4 mmol/L and HDL-C of
0.6560.13 mmol/L (control group). TC and TG levels were
reduced by niacin (239%, P,0.001; 250%, P,0.001), simvas-
tatin (230%, P,0.001; 219%, NS) and the combination (255%,
P,0.001; 252%, P,0.001). The combination reduced TC to a
greater extent than simvastatin alone (236%, P,0.001). Niacin
increased HDL-C by +28% (P,0.01) as compared to the control,
whereas the combination increased HDL-C by +14% (P,0.05) as
compared to simvastatin mono-treatment. Niacin alone resulted in
higher HDL-C than the combination (P,0.001). The reductions
in plasma TC induced by niacin, simvastatin and the combination
were confined to apoB-containing lipoproteins as measured after
lipoprotein separation by FPLC (Figure 1D).
Niacin Reduces ApoB-containing Lipoprotein Cholesterol
by Modestly Increasing VLDL Clearance Without
Affecting VLDL Production
To determine by which mechanism the level of apoB-containing
lipoprotein cholesterol is decreased, first the VLDL-TG produc-
tion was assessed after injection of Tran35S label and tyloxapol.
VLDL-TG production did not differ between controls and niacin-
treated mice (Figure 2A; control 6.160.7 mmol/mL/h versus
niacin 6.260.8 mmol/mL/h; P= 0.94). In addition, the apoB
production rate, as measured by incorporation of 35S-activity in
the VLDL fraction (Figure 2B; control 2.960.5 mmol/mL/h
versus niacin 2.960.4 mmol/mL/h; P= 0.94) and VLDL-apoB
lipidation (control 1.360.4 nmol/100 dpm versus niacin
1.460.3 nmol/100 dpm; P= 0.69) did not differ between groups.
Figure 1. Effect of niacin, simvastatin and their combination on plasma lipid levels. Plasma total cholesterol (A), triglycerides (B) and HDL-
cholesterol levels were measured at various time points throughout the study. The average HDL-cholesterol levels were calculated for all the
treatment groups (C). Lipoproteins were separated by FPLC and cholesterol was measured in the fractions after 18 weeks of treatment (D). (Simva,
simvastatin; values are means 6 SD; n = 15 per group; **P,0.01 and ***P,0.001 as compared to control; #P,0.05 and ###P,0.001 as compared to
niacin+simvastatin).
doi:10.1371/journal.pone.0066467.g001
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Figure 2. Effect of niacin on VLDL production and clearance. To determine VLDL production, mice were injected with Trans35S label and
tyloxapol and the accumulation of TG in plasma (A) and the production rate of VLDL-TG and apoB, as well as VLDL lipidation, defined as the ratio of
VLDL-TG/apoB, were determined (B). To determine VLDL clearance, mice were injected with glycerol tri[3H]oleate- and [14C]cholesteryl oleate-labeled
VLDL-like emulsion particles. Plasma 3H-activity was determined as percentage of the initial dose (C), and uptake of 3H-activity by various organs was
determined as percentage of the injected dose per gram wet tissue (D). (BAT, brown adipose tissue; gonWAT, gonadal white adipose tissue; subWAT,
subcutaneous white adipose tissue; visWAT, visceral white adipose tissue; values are means 6 SD; n = 6 per group for VLDL production and n= 3–5
per group for VLDL clearance; *P,0.05 as compared to control).
doi:10.1371/journal.pone.0066467.g002
Table 1. The effect of niacin, simvastatin and their combination on plasma CETP activity after 4 and 18 weeks of treatment, as well
as plasma CETP mass and hepatic CETP expression after 18 weeks of treatment.
Average plasma CETP activity
(nmol/mL/h) Plasma CETP mass (mg/mL)
Hepatic CETP expression
(% of control)
Control 64.3611.4 21.363.4 100630
Niacin 50.666.6 ** 16.663.5 ** 76623 P = 0.072
Simva 48.168.4 *** 13.463.5 *** 76625
Niacin+Simva 42.668.9 *** P = 0.081 11.062.2 *** P = 0.050 58633 P = 0.059
CETP, cholesteryl ester transfer protein; Simva, simvastatin. Values are means 6 SD (n = 15 per group for plasma CETP activity and mass and n= 6–8 per group for
hepatic CETP expression). **P,0.01 and ***P,0.001 as compared to control.
doi:10.1371/journal.pone.0066467.t001
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We then examined the clearance and uptake of [3H]TO and
[14C]CO-labeled VLDL-like emulsion particles. Despite lack of
statistical power, due to unexpected loss of mice, there was a trend
towards a faster plasma clearance rate of [3H]TO (Figure 2C
control t1/2 = 6.462.2 min versus niacin t1/2 = 4.960.9 min;
P = 0.19) and a significantly faster initial [3H]TO clearance in
the first 5 min after niacin treatment (P,0.05). Tissue-specific 3H-
accumulation did not differ between groups, although there was a
tendency (P= 0.07) for a higher 3H-accumulation in the spleen
from the niacin-treated mice (Figure 2D). This was accompanied
by a non-significant increase in the plasma clearance rate of
[14C]CO (control t1/2 = 11.665.5 min versus niacin t1/
2 = 7.161.7 min; P= 0.12) with no differences in
14C-accumula-
tion in the various organs between groups (data not shown).
Niacin, Simvastatin and their Combination Reduce
Plasma CETP Activity, CETP Mass and Niacin alone and
together with Simvastatin Reduces Hepatic CETP Gene
Expression
In a previous study, we showed that niacin increased HDL-C by
decreasing hepatic CETP expression and plasma CETP concen-
tration [18]. To verify this, we measured plasma CETP activity
and mass and hepatic CETP mRNA expression after 4 and/or 18
weeks of treatment (Table 1). Niacin, which most prominently
increased HDL-C, reduced the average plasma CETP activity by
221% (P,0.01) and mass by 222% (P,0.01). Simvastatin
reduced CETP activity and mass by 225% and 237%,
respectively (both P,0.001) without affecting HDL-C levels.
The combination reduced CETP activity (234%; P,0.001) and
mass (248%; P,0.001) to an even higher extent. Previously, we
demonstrated that this reduction was due to reduced CETP
mRNA expression in the liver. In line with these results, we found
that niacin alone and in combination with simvastatin tended to
reduce hepatic CETP expression to 276% (P=0.072) and 258%
(P= 0.059), respectively. Besides the liver, WAT is considered as a
major source of CETP and since WAT is a target of niacin [29],
we also determined the effect of all treatments on CETP mRNA
expression in WAT. Niacin did not decrease CETP expression in
WAT (data not shown), which is consistent with a recent study in
CETP transgenic mice [30]. For the control group, a 125 times
lower relative CETP expression was measured in WAT compared
to the liver (data not shown). A mild correlation was found
between hepatic CETP expression and plasma CETP mass
Figure 3. Effect of niacin, simvastatin and their combination on plaque morphology. Representative images of hematoxylin-phloxine-
saffron-stained atherosclerotic lesions in a cross section of the aortic root area for the control group (A), niacin group (B), simvastatin group (C) and
the combination group (D) after 18 weeks of treatment.
doi:10.1371/journal.pone.0066467.g003
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(R2= 0.25, P= 0.006), whereas CETP expression in WAT did not
correlate with plasma CETP mass (R2 = 0.02, P = 0.45) (data not
shown). Taken together, we concluded that the liver is the major
determinant for circulating CETP levels in this model, which were
affected by all the treatments.
Niacin alone and in Combination with Simvastatin
Reduces Atherosclerosis Development to a Greater
Extent than Simvastatin Treatment alone
After 18 weeks of treatment, we measured the effect of niacin,
with and without simvastatin on atherosclerosis development in
the aortic root. Figure 3 illustrates representative images of
atherosclerotic lesions for each group. We determined the number
of lesions per cross section (Figure 4A), the lesion severity as a
percentage of all lesions (Figure 4B), the percentage undiseased
segments (Figure 4C) and the total lesion area per cross section
(Figure 4D). To determine lesion severity as a percentage of all
lesions, type I-III lesions were classified as mild lesions and type
IV–V lesions were classified as severe lesions.
In the control group, a fair amount of atherosclerosis developed
with 3.560.9 lesions per cross section, of which 62616% were
severe and only 17616% undiseased segments. The total lesion
area was 1446636103 mm2 per cross section. When compared to
the control, niacin reduced the number of lesions (223%;
P= 0.056), attenuated lesion severity (P,0.001) and increased
the percentage undiseased segments (+141%, P,0.001). Further-
more, niacin strongly decreased the total lesion area by 278%
(P,0.001). Simvastatin alone was less effective as it only reduced
lesion severity (P,0.01) and total lesion area (249%, P,0.01).
The combination had potent inhibiting effects on lesion develop-
ment, as evidenced by reductions in lesion number (248%,
P,0.001), severity (P,0.001) and area (287%, P,0.001), and by
an increase in the percentage of undiseased segments (+210%,
P,0.001). Furthermore, the percentage undiseased segments, as
well as the reduction in the lesion number and area was greater
after the combination compared to simvastatin alone (244%;
+110%; 274%, all P,0.01). These results showed that niacin
mono-treatment was very potent in inhibiting atherosclerotic
lesion development in APOE*3Leiden.CETP mice and that niacin
added to the atherosclerosis-reducing effects of simvastatin.
Figure 4. Effect of niacin, simvastatin and their combination on atherosclerosis development in aortic root area. After 18 weeks of
treatment, number of lesions (A), lesion severity (B), percentage undiseased segments (C) and total lesion area (D) were determined per cross section.
Lesion severity was classified as mild (type I–III) and severe (type IV–V) lesions. (Simva, simvastatin; values are means6 SD; n= 15 per group; **P,0.01
and ***P,0.001 as compared to control; ##P,0.01 as compared to niacin+simvastatin).
doi:10.1371/journal.pone.0066467.g004
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Niacin Improves Lesion Stability Index and Decreases
Functional Markers of Vascular Inflammation
After investigation of lesion morphology, we analyzed the
treatment effects on plaque composition. For all lesions, the
macrophage area as destabilization factor (Figure 5A), as well as
SMC (Figure 5B) and collagen area (data not shown) as
stabilization factors were calculated per cross section. The
macrophage, SMC and collagen area per cross section in the
control group were 24.368.66103 mm2, 4.662.36103 mm2 and
64.2637.06103 mm2, respectively. All treatments reduced the
macrophage (273%, 252% and 290%; all P,0.001) and the
SMC area (266%, P,0.01; 250%, P,0.01; 279%, P,0.001).
As a measure of the lesion stability index, the ratio of collagen and
SMC area (i.e. stabilization factors) to macrophage area (i.e.
destabilization factor) was determined for all lesions (data not
shown). The lesion stability ratio for the control group was
Figure 5. Effect of niacin, simvastatin and their combination on lesion composition. Macrophage area (A) and SMC area (B) were
determined for all lesions and calculated per cross section. To correct for lesion size, macrophage content (C), SMC content (D), as well as plaque
stability index (ratio of collagen and SMC content to macrophage content) (E) were also calculated as a percentage of lesion area, specifically in
severe lesions (Type IV–V). (Simva, simvastatin; SMC, smooth muscle cells; values are means 6 SD; n = 15 per group; *P,0.05, **P,0.01 and
***P,0.001 as compared to control; #P,0.05, and ###P,0.001 as compared to niacin+simvastatin).
doi:10.1371/journal.pone.0066467.g005
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2.761.4. Combination treatment tended to increase this ratio by
+201% (P= 0.085).
After finding indications for more stable lesions, we specifically
focused on the composition of the more severe lesions, which are
considered to be the most vulnerable lesions. Additionally, we
corrected for the lesion area. Thus, we measured the macrophage
(Figure 5C), SMC (Figure 5D) and collagen content (data not
shown) as a percentage of lesion area. The severe lesions in the
control group consisted of 20% macrophages, 4% SMC and 45%
collagen (latter data not shown). Niacin alone and in combination
with simvastatin reduced the relative macrophage content by -
18% (NS) and 254% (P,0.001), respectively and increased the
relative SMC content by +97% (P,0.01) and +102% (P,0.05),
respectively. The combination was superior to simvastatin mono-
treatment in stabilizing the plaque as seen by a reduction in
macrophage content (254%; P,0.05) and an increase in SMC
content (+79%; P=0.057). There were no significant differences in
collagen content between groups (data not shown). The lesion
stability index was also calculated for the severe lesions based on
the relative area (Figure 5E). Combination treatment increased
this ratio by +371% (P,0.01) compared to the control (2.661.0)
and to a greater extent compared to simvastatin (P,0.05) alone.
As functional markers of vessel wall inflammation, the number
of monocytes adhering to the activated endothelium (Figure 6A)
and T cells in the aortic root area (Figure 6B) were counted and
calculated per cross section. In the control group, 3.861.2
adhering monocytes and 11.368.3 T cells were present. A
marked reduction of adhering monocytes of more than 245%
(P,0.01; P,0.01 and P,0.001, respectively) was found in all
treatment groups, where T cells abundance was reduced by niacin
alone (271%, P,0.01) and in combination with simvastatin
(281%, P,0.001).
Niacin Reduces Atherosclerosis Progression Primarily by
Reducing NonHDL-Cholesterol
In addition to inflammation, plasma cholesterol is certainly a
strong determinant for atherosclerosis progression. We evaluated
whether the anti-atherogenic effect of niacin and simvastatin could
be explained by the reduction in plasma TC (Figure 7). Since
atherosclerotic lesion area showed a quadratic dependence on
plasma TC exposure, lesion area was transformed using a square
root transformation. Lesion area was strongly predicted by plasma
TC exposure (R2 = 0.70, P,0.001; Figure 7A), and nonHDL-C
exposure (R2 = 0.69, P,0.001; Figure 7B) and to a much lesser
extent by HDL-C exposure (R2 = 0.20, P,0.001; Figure 7C).
Together, nonHDL-C and HDL-C exposure accounted for 71%
of the variability in lesion area and predicted the lesion area
independently of each other (P,0.001 and P,0.05, respectively).
Importantly, the effects of niacin and simvastatin on lesion area
were lost after correcting for both HDL-C and nonHDL-C
exposure (P= 0.16; P = 0.61, respectively). Furthermore, no effect
of niacin and simvastatin on monocyte adhesion was found after
correcting for nonHDL-C exposure (P= 0.50; P = 0.20, respec-
tively). However, niacin decreased the square-root transformed
macrophage area and T cell abundance even after correcting for
nonHDL-C exposure (both P,0.01), whereas simvastatin did not
(P = 0.12; P= 0.26, respectively).
Collectively, these data are compatible with a mechanism that
niacin and simvastatin mainly decrease atherosclerotic lesion
development via a reduction of nonHDL-C with an additional
effect of HDL-C-elevation for niacin, while a direct effect on lesion
macrophages and T cell abundance may contribute to the anti-
atherogenic effect of niacin, but not simvastatin.
Niacin Mildly Increases Reverse Cholesterol Transport
To investigate the possible mechanism by which the HDL-C-
raising effect of niacin may contribute to its anti-atherogenic effect,
we performed an in vivo RCT experiment. After 3 weeks of
treatment, mice were injected with [3H]-cholesterol-labeled
macrophages. Forty eight hours after injection, plasma total 3H-
activity tended to be decreased (236%, P=0.065), whereas 3H-
activity in the HDL fraction was increased after niacin treatment
(+155%, P,0.01; Figure 8A). In addition, niacin increased 3H-
activity in the liver (+33%; P,0.05) and tended to increase fecal
3H-activity (+26%; P=0.065; Figure 8B).
Discussion
In this study, we aimed to address the discrepancy between the
beneficial effects of niacin in initial clinical trials [3–6,14] and the
lack of effect of niacin on top of statin treatment on reduction of
cardiovascular events in the AIM-HIGH [8] and HPS2-THRIVE
[7] trials by investigating the effects of niacin without and with
simvastatin on atherosclerosis development and determine the
underlying mechanisms in APOE*3Leiden.CETP mice, a mouse
model for familial dysbetalipoproteinemia (FD). We demonstrated
Figure 6. Effect of niacin, simvastatin and their combination on monocyte adhesion and T cell number. The number of monocytes
adhering to the endothelium (A) and the number of T cells in the aortic root area (B) were determined per cross section. (Simva, simvastatin; values
are means 6 SD; n = 15 per group; **P,0.01; ***P,0.001 as compared to control; ###P,0.001 as compared to niacin+simvastatin).
doi:10.1371/journal.pone.0066467.g006
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that niacin decreased atherosclerosis development mainly by
reducing nonHDL-C with a modest HDL-C-raising and anti-
inflammatory effect and that the additive effect of niacin on top of
simvastatin was mostly dependent on its nonHDL-C-lowering
capacities.
First, we showed that niacin and simvastatin both reduced
plasma lipid levels. Niacin reduced (V)LDL-C and (V)LDL-TG
and increased HDL-C, whereas simvastatin mainly reduced
(V)LDL-C. Combination treatment of niacin and simvastatin
reduced nonHDL-C more effectively as compared to simvastatin
alone. In our study, the reduction in plasma TC after niacin
treatment alone and in combination with simvastatin was greater
compared to recent clinical trials. The APOE*3Leiden mouse was
initially developed as an animal model for FD or type III
hyperlipoproteinemia, which is characterized by elevated levels of
cholesterol and an increased ratio of cholesterol to TG in the
VLDL and intermediate density lipoprotein (IDL) fractions,
resulting in the appearance of b-VLDL particles [31,32]. Similarly
as in FD patients, in APOE*3Leiden and APOE*3Leiden.CETP
mice as a model for mixed dyslipoproteinemia, a major part of
plasma cholesterol is contained in the VLDL and VLDL-remnant
particles, leading to formation of b-VLDL particles, which further
increases after cholesterol feeding. Whereas niacin reduces plasma
TC by ,5–15%, LDL-C by ,5–20% and TG by ,15–30% in
patients with hyperlipidemia [2], in two small studies in FD
patients, niacin decreased TC by 23–50% and TG by 43–62%
[33,34] with -56% reduction of VLDL-C and 48% reduction of
VLDL-TG [34]. Thus, the extent of lipid-lowering observed with
niacin in APOE*3Leiden.CETP mice is comparable to that of FD
patients.
Since plasma VLDL-TG and apoB levels are determined by the
balance between VLDL production and clearance, we evaluated
their individual contribution. VLDL production was not affected
in niacin-treated mice, neither was apoB production or lipidation
of the VLDL particle. However, a modest effect of niacin on
VLDL clearance was observed. The mechanism behind the lipid-
lowering effect of niacin has been generally ascribed to a reduced
hepatic VLDL production, as a result of decreased free fatty acid
(FFA) flux from WAT after inhibition of hormone sensitive lipase.
However, an initially decreased FFA flux is followed by a rebound
effect with increased release of FFA [1,35]. In humans, contra-
dicting data describe that niacin decreased VLDL production
without affecting VLDL clearance [36–38] and on the other hand
that niacin enhanced clearance of apoB without affecting
production [39]. The latter study is in line with our results, which
implicate VLDL clearance rather than VLDL production as the
possible mechanism by which niacin reduces apoB.
The niacin-induced increase in HDL-C in the present study
may be attributed to a decrease in hepatic and plasma CETP
leading to an inhibition of HDL delipidation as previously
described [18]. As similar effects on CETP levels and activity
were observed after simvastatin treatment, without affecting HDL,
different mechanisms are likely involved in either treatment.
Interestingly, a decreased macrophage content accompanying
decreased hepatic cholesterol accumulation as a result of niacin’s
lipid-lowering effect was recently proposed as a mechanism by
which niacin decreases hepatic CETP expression [30].
An important observation from our studies is that niacin
decreases atherosclerosis progression and adds to the anti-
atherogenic effect of simvastatin, in particular regarding its
enhancing effect on plaque stability. Niacin decreased lesion
number, severity and area, and increased the percentage
undiseased segments. Moreover, niacin improved lesion compo-
sition by reducing the macrophage content and increasing the
SMC content. Importantly, the combination treatment increased
the plaque stability index, defined as the ratio of SMC and
Figure 7. Correlation between plasma cholesterol exposure
and lesion area. The square root of the lesion area was plotted
against total cholesterol exposure (A), nonHDL-cholesterol exposure (B)
and HDL-cholesterol exposure (C). Linear regression analyses were
performed. (Simva, simvastatin; n = 15 per group).
doi:10.1371/journal.pone.0066467.g007
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collagen over macrophage area, as compared to either niacin or
simvastatin alone.
It is interesting to speculate on the mechanism(s) underlying the
anti-atherogenic effect of niacin. In the APOE*3Leiden.CETP
mouse model, statistical analyses revealed that the effects of niacin
and simvastatin were largely explained by their reduction in
nonHDL-C, as evidenced by a strong correlation between plasma
nonHDL-C and lesion area. The fact that the combination
treatment reduced nonHDL-C beyond the level reached by
simvastatin alone can thus largely explain why niacin added to the
anti-atherosclerotic effect of simvastatin. Though, HDL-C also
appeared to predict lesion area independent of nonHDL-C, albeit
that the predictive value of HDL-C was much smaller than that of
nonHDL-C. The HDL-C-raising effect of niacin, may, therefore,
have contributed to some extent to the anti-atherosclerotic activity
of niacin.
To explore the contribution of the niacin-induced increase in
HDL-C to the reduction of atherosclerosis, we investigated the
functionality of HDL by performing an RCT experiment. From
this experiment, we conclude that the effect of niacin on RCT may
partially contribute to, but is not the driving force behind its anti-
atherogenic effects. This is in accordance with our statistical
correlations, which showed nonHDL-C to be a much stronger
contributor to atherogenesis. Although HDL-C contributed to
some extent, we observed that niacin’s attenuating effect on
atherosclerosis development in APOE*3Leiden.CETP mice, fed a
Western-type diet with 0.1% cholesterol, is largely explained by its
lipid-lowering effect. At first sight, this seems to contradict a recent
report showing that niacin reduced atherosclerosis development in
LDL receptor-deficient mice under conditions that left plasma
cholesterol levels unaffected [15]. In that mouse model, the
atheroprotective effects of niacin were mainly explained by
impaired homing macrophage recruitment to atherosclerotic
plaques and by promoting cholesterol efflux from macrophages
by upregulation of ABCG1. However, it should be noted that
those mice were fed a high fat diet containing as much as 1.5%
cholesterol. A previous study from our laboratory showed that
dietary cholesterol induced dose-dependent marked inflammation
in mice [40], where the liver switches to an inflammatory, pro-
atherosclerotic state as reflected by a strong increase in serum
amyloid A levels at dietary cholesterol levels exceeding 0.5%.
Previously, Lukasova et al. [15] evaluated the anti-atherogenic
effect of niacin under highly inflammatory conditions, at which the
anti-inflammatory properties of niacin may become dominant and
may not necessarily reflect the mode of action for niacin under
mild cholesterol intake as used in the present study.
It should be noted that we also obtained evidence that niacin
exerted anti-inflammatory effects in our mouse model under
milder dietary conditions. Firstly, niacin reduced monocyte
adhesion and macrophage area of the atherosclerotic lesions. In
fact, niacin reduced macrophage area independent of nonHDL-C,
whereas simvastatin did not. These data not only corroborate the
findings in LDL receptor-deficient mice [15], but also the recent
observations that niacin reduced collar-inflicted vascular inflam-
mation and inhibited intima-media neutrophil recruitment in New
Zealand White rabbits independent of changes in plasma lipids
[41]. Secondly, we observed that niacin, but not simvastatin,
strongly reduced the number of T cells in the aortic root area,
which are involved in the progression of atherosclerosis [42]. The
reduction was independent of nonHDL-C exposure, suggesting
the anti-inflammatory effect observed was brought about by
niacin, instead of HDL derived. This is in accordance with a study
where niacin inhibited monocyte chemotactic protein 1 (MCP-1),
RANTES and fractalkine in adipocytes. These chemokines
contribute to the recruitment of T cells and macrophages. WAT
is known to express the GPR109A receptor and has the ability to
contribute to both systemic and local (perivascular) inflammation
associated with atherosclerosis [29,43].
Although initial clinical studies showed that niacin reduced
atherosclerosis development in combination with statins [3–5] and
reduced the relative risk of cardiovascular events [6], results from
the large outcome trials AIM-HIGH and HPS2-THRIVE did not
confirm earlier findings [8,44,45]. In order to test the HDL
hypothesis, the AIM-HIGH investigators minimized the differ-
ences in LDL levels between the groups. Patients enrolled in the
trial were subjected to aggressive LDL-C-lowering treatment,
aimed at LDL-C of 40–80 mg/dL (1.03–2.07 mmol/L), reaching
mean baseline LDL-C of 71 mg/dL (1.84 mmol/L) and HDL-C
of 35 mg/dl (0.91 mmol/L) [46]. A modest increase in HDL-C
was observed in the placebo group, resulting in a 4–5 mg/dl
(0.10–0.13 mmol/L) difference in HDL-C between groups. This,
together with the aggressive LDL-C-lowering may have given rise
to insufficient power to detect a reduction in events [45].
Unexpectedly, the much larger outcome trial HPS2-THRIVE
failed to reveal further cardiovascular risk reduction when adding
ER-niacin/laropiprant to vigorous statin treatment, plus if
Figure 8. Effect of niacin on reverse cholesterol transport. [3H]-cholesterol-labeled macrophages were injected in control and niacin-treated
mice and 3H activity was determined in plasma and HDL (A) and the liver 48 h after injection, as well as in feces collection between 0–48 h after
injection (B). (Values are means 6 SD; n = 8 per group; *P,0.05 and ** P,0.01 as compared to control).
doi:10.1371/journal.pone.0066467.g008
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required ezetimibe, as compared to statin/(ezetimibe) mono-
treatment [7]. Furthermore, there was a significant increase in
non-fatal serious adverse events and drop-out rate in the ER-
niacin/laropiprant-treated patients. The lack of inclusion criteria
for HDL-C resulted in a baseline HDL-C of .40 mg/dl
(1.14 mmol/L) with a low baseline LDL-C level of ,70 mg/dl
(1.64 mmol/L). Patient stratification revealed that baseline HDL-
C levels did not predict efficacy of niacin and that indeed only in
patients with high LDL-C niacin reduced major cardiovascular
events.
In conclusion, our results show that niacin decreases athero-
sclerosis development mainly by reducing nonHDL-C with
modest HDL-C-raising and additional anti-inflammatory effects.
The additive effect of niacin on top of simvastatin is mostly
dependent on its nonHDL-C-lowering capacities. These data
suggest that clinical beneficial effects of niacin are largely
dependent on its ability to lower LDL-C on top of concomitant
lipid-lowering therapy and may explain the failure of niacin in the
clinical outcome trials.
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